IP Library Granted Patent US 10,328,070
Granted Patent B1
US 10,328,070 · App. 16/201,067 · Granted Jun 25, 2019

Polymorphic forms of naltrexone

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,328,070
App. No.
16/201,067
Granted
Jun 25, 2019
Kind
B1
Abstract

This invention relates to the discovery of novel polymorphic forms of naltrexone, including solvates, hydrates, anhydrous and other crystalline forms and combinations thereof. These novel forms of naltrexone impart advantages in pharmaceutical formulations incorporating them, including sustained release, or long acting, formulations.

Claims (10)

1. A polymorphic form of naltrexone dimethylformamide solvate which is characterized by at least one of:

(a) the X-ray powder diffraction pattern of FIG. 2A ;

(b) the differential scanning calorimetry thermogram of FIG. 14A ; and

(c) the IR-ATR spectrum of FIG. 26A .

2. A pharmaceutical composition comprising the polymorphic form according to claim 1 and a pharmaceutically acceptable carrier.

3. A polymorphic form of naltrexone dimethylformamide solvate which is characterized by at least one of:

(a) the X-ray powder diffraction pattern of FIG. 2B ;

(b) the differential scanning calorimetry thermogram of FIG. 14B ; and

(c) the IR-ATR spectrum of FIG. 26B .

4. A pharmaceutical composition comprising the polymorphic form according to claim 3 and a pharmaceutically acceptable carrier.

Assignments (2)
RELEASE OF PATENT SECURITY AGREEMENTS Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0701 →
SECURITY INTEREST Recorded Mar 20, 2020
From: ALKERMES PHARMA IRELAND LIMITED
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 052914/0832 →